Exelixis drug improves overall survival in liver cancer patients

(Reuters) – Exelixis Inc’s drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company’s shares soaring 31 percent.

Source: Reuters Health News